NIAID scientists have discovered that Rostafuroxin, a synthetic digitoxigenin derivative, inhibits RSV infection in respiratory epithelial cells by inhibiting the RSV induced ATP1A1-mediated signaling pathway required for RSV entry. Rostafuroxin is a promising anti-viral drug candidate for RSV and possibly other viruses that use the same pathway for host cell entry.

NIAID Technology Transfer and Intellectual Property Office

Nov 27, 2018

Sponsor content

Fusion Glycoprotein Vaccine for Human Metapneumovirus: Licensing Opportunity

Investigators at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) have generated an hMPV fusion glycoprotein (“F protein”) stabilized in a prefusion conformation. The prefusion stabilized F protein immunogen can be delivered as either an isolated homotrimer or trimers displayed on a nanoparticle. These immunogens elicit broad and potent hMPV-neutralizing antibodies.

NIAID Technology Transfer and Intellectual Property Office

Nov 27, 2018

Sponsor content

ANTIBODIES AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF EPSTEIN-BARR VIRUS INFECTION: Collaboration and Licensing Opportunity

Scientists at the NIAID are developing neutralizing antibodies, originally isolated from humans or non-human primates, that could be useful in preventing primary infection or reactivation of EBV in immunocompromised individuals. These antibodies are 10-100 times more potent than the most potent EBV neutralizing antibody identified to date (72A1).

NIAID Technology Transfer and Intellectual Property Office

Nov 27, 2018

Sponsor content

Middle East Respiratory Syndrome Coronavirus Antibodies: Collaboration and Licensing Opportunity

Inventors at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases have identified and developed neutralizing monoclonal antibodies (nMAbs) against the MERS-CoV. In preclinical testing, these nMAbs have demonstrated potent protective effects, preventing death, viral replication in the lower airways and severe disease in challenge studies with mice.

NIAID Technology Transfer and Intellectual Property Office

Nov 27, 2018

Sponsor content

Universal Influenza Virus Probes for Enrichment of Influenza Viral Sequences

This probe set can capture and enrich influenza viral sequences selectively and effectively in a variety of samples, such as clinical samples with degraded nucleotides or samples containing very low amounts of influenza virus, thus making it a valuable tool for influenza virus diagnoses and surveillance.

NIAID Technology Transfer and Intellectual Property Office

Nov 27, 2018

Sponsor content

Methods for Dagnosing and Treating Mycobacterium tuberculosis (Mtb) Infection through Detection of CD153 Expression Level: Collaboration and Licensing Opportunity

NIAID researchers have discovered that the expression of TNF superfamily molecule CD153 (TNSF8) is required for control of the pulmonary Mtb infection by CD4 T cells. Since the expression of CD153 by CD4 T cells is a major immune mechanism of host protection against Mtb infection, the discovery can be used to effectively diagnose and treat Mtb infections in the future.

NIAID Technology Transfer and Intellectual Property Office

Nov 27, 2018

Sponsor content

Optimized variants of the broadly neutralizing HIV-1 gp41 antibody, 10E8

Optimized variants broadly neutralizing HIV-1 gp41 antibody, 10E8, exhibit improved manufacturing properties, while preserving neutralizing breadth and potency.

NIAID Technology Transfer and Intellectual Property Office

Nov 27, 2018

Sponsor content

Recombinant HIV-1 Envelope Proteins and Their Use: Licensing Opportunity

Researchers at the VRC/NIAID have stabilized the conformation of the Env trimer of HIV-1 so that it displays the epitopes known to elicit broadly neutralizing antibodies. This stabilized Env trimer is termed BGSOSIP505 and is useful as an HIV vaccine candidate.

NIAID Technology Transfer and Intellectual Property Office

Nov 27, 2018

How to attract a biopharma partner

Editorial content

November 2018